According to CCTV News, on April 8, there was news that the United States would impose tariffs on drugs. It is understood that the broad tariffs on US imports announced last week did not involve drugs, but at that time, it was reported that drugs would face separate tariffs. Pharmaceutical companies such as Hanyu Pharmaceutical, Kelun Pharmaceutical, and Tonghua Dongbao responded.

Hanyu Pharmaceutical responded on April 9: "The company's current products sold to the United States are mainly liraglutide and some raw materials. We and our partners are closely following the relevant developments. The relevant response needs to be studied after the specific situation of the US drug tariffs is clarified. The company has also been planning to expand into the European or Southeast Asian markets to reduce its dependence on the US market."

Kelun Pharmaceutical's Securities Department responded: "We have just seen this news. The company's relevant departments are paying close attention. The company's products exported to the United States include preparations and raw materials. They do not account for a large proportion of the company's overall revenue. The specific impact depends on the situation after the tariffs are implemented. It is impossible to make a clear judgment now."

Recently, it was stated that the company has no products exported to the United States, so the current US tariff policy has no impact on the company's production and operations. Data shows that the company's overseas revenue in 2024 will be about 100 million yuan, accounting for a small proportion of total revenue, and the current national policy environment for exports is relatively stable. Tonghua Dongbao said that the company will continue to pay close attention to changes in the international environment, flexibly respond to the complex and changing external environment, and ensure the company's long-term stable development.

It is reported that the pharmaceutical industry trade lobbying organization EFPIA (whose members include European pharmaceutical giants Bayer, Novartis, Novo Nordisk, etc.) said that it has called on the EU President to promote "rapid and fundamental action" to reduce the "risk of outflow" to the United States.

https://finance.eastmoney.com/a/202504103371942410.html